Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis

2017 ◽  
Vol 79 (2) ◽  
pp. 435-436
Author(s):  
Sarah Cargnin ◽  
Salvatore Terrazzino
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Predictors Of Response ◽  
Response To Chemotherapy

scholarly journals ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis

2017 ◽  
Vol 26 (4) ◽  
pp. 473-482 ◽  
Author(s):  
Adela Madrid-Paredes ◽  
Marisa Cañadas-Garre ◽  
Antonio Sánchez-Pozo ◽  
Manuela Expósito-Ruiz ◽  
Miguel Ángel Calleja-Hernández
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Gene Polymorphisms ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Abcb1 Gene ◽  
Response To Chemotherapy

Multi-drug resistance and breast cancer: A meta-analysis of MDR1 and its functional significance

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11010-11010 ◽  
Author(s):  
B. Trock ◽  
F. Leonessa ◽  
R. Clarke
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Clinical Response ◽  
Meta Analysis ◽  
Significant Risk ◽  
Multi Drug Resistance ◽  
Active Efflux ◽  
Sestamibi Imaging ◽  
Response To Chemotherapy ◽  
Reversing Agents

11010 Background: The clinical significance of MDR1 as a mechanism of multidrug resistance in breast cancer has not been established. We conducted a meta-analysis examining MDR1/gp170 in breast cancer, significantly updating a meta-analysis we performed in 1997. Methods: Published papers on MDR1/gp170 and breast cancer were identified by searching literature databases and bibliographies of published papers. Pooled relative risks (RR) for association between MDR1/gp170 expression and clinical outcomes were estimated with the Mantel-Haenszel method. Results: 84 studies were included in analysis: 63 measured MDR1/gp170 expression, 21 measured response to chemotherapy, 11 used sestamibi imaging, and 11 evaluated multidrug resistance reversing agents. MDR1 expression was detected in 45.9% of breast tumors prior to treatment and 66.8% of tumors after treatment (p<0.0001). There were no significant differences in gp170 expression by antibody type (p=0.567). In 11 studies, MDR1/gp170 expression after chemotherapy was associated with a significant risk of non-response, RR=1.79 (95% CI=1.35, 2.35), p<0.0001. This effect was lower in 13 studies with MDR1/gp170 assessed prior to chemotherapy, RR=1.28 (1.06, 1.55), p=0.009. Only 7 of 16 studies showed significant associations with decreased progression-free or overall survival. Of 11 sestamibi imaging studies, 10 showed a significant association between shorter retention and higher levels of MDR1/gp170, suggesting active protein pumping of contrast agent. None of 11 studies of multidrug reversing agents found >25% of refractory patients improving to partial clinical response, but most studies did not confine treatment to patients with MDR1/gp170 expression. Conclusions: This meta-analysis includes nearly 3 times as many studies as our 1997 analysis. MDR1 is expressed in approximately half of breast cancer patients, and is induced by chemotherapy. MDR1 after chemotherapy is associated with RR=1.8 for failure to achieve a clinical response, and RR=1.3 without induction by chemotherapy. Sestamibi gives the strongest support for active efflux of agent by gp170, but studies with MDR reversing agents have shown little success, which may partly reflect poor study design. [Table: see text]

Can [F-18]FDG PET imaging predict early response to chemotherapy in breast cancer patients?

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e14577-e14577
Author(s):  
C. S. John ◽  
R. Madabushi ◽  
C. Farah ◽  
C. Lubas ◽  
G. Williams
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Pet Imaging ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Early Response ◽  
Drug Uptake ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Response To Chemotherapy

e14577 Background: The purpose of this study was to perform a meta-analysis of literature data and see if [F-18]FDG and PET imaging can be used to predict the early response to chemotherapy based upon the measure of standard uptake value (SUV) or drug uptake ratio (DUR; a measure of glycolytic index) in breast cancer patients. This intervention may identify the responders for continued therapy or identify the non- responders for change of therapy. Methods: A literature search determined the number of studies that used PET-FDG imaging to monitor the response of various chemotherapies in breast cancer patients. A total of nine studies have been reviewed that used SUV/DUR as a measure of glycolytic activity of the primary tumors. The percent decrease of SUV over baseline was determined for chemotherapy cycle 1 and for subsequent cycles. A paired t-test was performed to see the statistical significance of the SUV decrease. Results: Five (n=158) studies presented the data in % mean reduction in SUV and four (n=59) studies presented SUV values for the individual patient. The average decrease in SUV in responders were 29% and 51% after first and second cycle, respectively. The non responders did not show significant change in SUV as compared to responders. Conclusion: The preliminary data mining and analysis strongly implies that PET imaging using [F-18]FDG may be used to monitor the progress of chemotherapy in breast cancer patients. This study was supported by a grant from OWH, FDA. The results do not represent official FDA position. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document